SDHAF1: A Protein Interaction and Cancer Target (G644096)

Target Name: SDHAF1

NCBI ID: G644096

SDHAF1

SDHAF1: A Protein Interaction and Cancer Target

SDHAF1 (lyrm8) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the superfamily of RNA-binding proteins (RBP), which includes proteins that regulate gene expression and play important roles in various cellular processes.

One of the unique features of SDHAF1 is its ability to interact with specific DNA sequences. This interaction is mediated by the protein's RNA-binding domain, which is composed of a nucleotide-binding oligomerization (NBO) domain and a conserved tortuous domain (CCDC ). The NBO domain is responsible for the protein's ability to form a stable complex with DNA, while the CCDC is involved in the protein's stability and functions as a scaffold.

SDHAF1's ability to interact with specific DNA sequences has important implications for its function in the cell. One of the ways that SDHAF1 regulates gene expression is by binding to specific DNA regions and modulating the activity of gene-specific transcription factors. For example, studies have shown that SDHAF1 can interact with the RNA polymerase II (RNA-P2) and the T-cell receptor (TCR) loci and can either activate or inhibit their activity depending on the specific context.

Another way that SDHAF1 regulates gene expression is by regulating microRNA (miRNA) levels. miRNA are small non-coding RNAs that play important roles in post-transcriptional gene regulation by binding to specific target genes. Studies have shown that SDHAF1 can interact with miRNA- containing regions in the genome and can either enhance or decrease the levels of certain miRNAs. This regulatory role for SDHAF1 is important for understanding how the cell communicates with itself and for the development of potential therapeutic strategies.

In addition to its role in gene regulation, SDHAF1 has also been shown to play an important role in the development and progression of various diseases. For example, studies have shown that SDHAF1 is overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This overexpression is thought to contribute to the development of cancer-related phenotypes, including increased invasiveness, metastasis, and poor patient outcomes.

Given the important role that SDHAF1 plays in regulating gene expression and the development of various diseases, it is a promising target for drug development. Several studies have identified potential small molecules that can interact with SDHAF1 and have shown promise in cell-based assays. For example, one study identified a small molecule called 1-fluoro-2-[3-(2-methylpropyl)amino]-2-propanethiol (FSP) that can interact with SDHAF1 and inhibit its activity. The results of this study suggest that FSP may be a useful therapeutic for the treatment of various diseases.

Another study identified a small molecule called 2-[3-(2-methylpropyl)amino]-1-propanethiol (SPH) that can also interact with SDHAF1. The results of this study suggest that SPH may be a potential therapeutic for the treatment of various diseases, including cancer.

While the potential therapeutic benefits of SDHAF1 are encouraging, it is important to consider the potential risks and adverse effects of drug development. The use of small molecules that can interact with SDHAF1 may be associated with various adverse effects, including systemic side effects and anaphylaxis. Additionally, the use of these small molecules may be limited by their effectiveness in animal models and their potential toxicities in humans.

In conclusion, SDHAF1 is a protein that is expressed in various tissues throughout the body and plays important roles in the regulation of gene expression and the development of various diseases. Its ability to interact with specific DNA sequences and its potential as a drug target make it an attractive target for further study and development. Further research is needed to fully understand the role of SDHAF1 in

Protein Name: Succinate Dehydrogenase Complex Assembly Factor 1

Functions: Plays an essential role in the assembly of succinate dehydrogenase (SDH), an enzyme complex (also referred to as respiratory complex II) that is a component of both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, and which couples the oxidation of succinate to fumarate with the reduction of ubiquinone (coenzyme Q) to ubiquinol (PubMed:24954417, PubMed:19465911). Promotes maturation of the iron-sulfur protein subunit SDHB of the SDH catalytic dimer, protecting it from the deleterious effects of oxidants (PubMed:24954417). May act together with SDHAF3 (PubMed:24954417). Contributes to iron-sulfur cluster incorporation into SDHB by binding to SDHB and recruiting the iron-sulfur transfer complex formed by HSC20, HSPA9 and ISCU through direct binding to HSC20 (PubMed:26749241)

The "SDHAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets